| Ytd | 67.62% | |
| 1y | 191.57% |
| Open | 7.67 | Prev Close | 7.63 | Low | 7.37 | High | 7.81 | Mkt Cap | 95.56M |
| Vol | 174.63K | Avg Vol | 103.84K | EPS | -0.76 | P/E | N/A | Forward P/E | -23.30 |
| Beta | 1.47 | Short Ratio | 1.54 | Inst. Own | 1.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.44 | 200-d Avg | 6.09 | 1yr Est | 7.50 |
NRXS News
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regula
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE
CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE
NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplet
NeurAxis, Inc. (NRXS) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 T
KODK and NRXS are worth watching for their growth.
NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and
NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.19) per share which beat the analyst consensus
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE A
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday'
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE A
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.18) per share which beat the analyst consensus
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE A
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE
NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs
Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.17) per share which beat the analyst consensus
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE
NeurAxis, Inc. (NASDAQ: NRXS - Get Free Report) fell 5.7% during trading on Thursday. The company tr
The new CPT code reflects the latest efficacious medical care available to patients, facilitating ad
Meta Platforms leads today???s Zacks Research Daily as AI-driven engagement and ad demand fuel growt
NeurAxis, Inc. (NASDAQ: NRXS - Get Free Report) shares rose 9.6% during mid-day trading on Wednesday
Craig-Hallum analyst Chase Knickerbocker maintains Neuraxis (AMEX:NRXS) with a Buy and raises the
NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical techno
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consens
NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology comp
